Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07830758 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Resmetirom in Patients With MASH and HFpEF

Name: Resmetirom in Patients With MASH and HFpEF — clinical trial record (NCT07830758)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorMadrigal Pharmaceuticals, Inc.

Started2026-09

View on ClinicalTrials.gov ↗

Madrigal Pharmaceuticals, Inc.

9 trials monitored

See all monitored trials

Heart Failure

1,854 trials monitored

See 95 trials at risk

NASH / MASH

645 trials monitored

See 22 trials at risk

This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). Participants are randomized 2:1 to resmetirom or placebo for 24 weeks.

Trial Details

NCT Number	NCT07830758
Lead Sponsor	Madrigal Pharmaceuticals, Inc.
Conditions	MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
Enrollment	90 participants
Start Date	2026-09
Primary Completion	2027-11 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-21